Pharma, under attack for drug prices, started an industry war

With national and state advertising campaigns, white papers and cartoon infographics, the powerful and well-funded drug industry lobby spent 2017 working to redirect public anger about drug prices to pharmacy benefits managers (or PBMs): links in the supply chain that sits invisibly between the patient and the drug maker — in the process bringing a long-simmering feud between two big health-industry players into the open.

Gerard Anderson is quoted.